Wednesday, May 27, 2015

Hot Life Sciences Companies To Invest In Right Now

Given that you clicked on this article, it seems safe to assume you either own stock in SVB Financial (NASDAQ: SIVB  ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about SVB Financial stock before deciding whether to buy, sell, or hold it.

SVB Financial is not your typical bank. Located in Northern California, it's the holding company for Silicon Valley Bank, a niche lender that focuses almost exclusively on companies in the technology, life sciences, and winery space. Think venture capital. "For nearly three decades," its website reads, "SVB Financial Group and its subsidiaries, including Silicon Valley Bank, have been dedicated to helping entrepreneurs succeed." And if its share-price performance is any indication, this model has succeeded. Over the past 10 years, the total return to shareholders has been 273%. For context, only a handful of banks exceeded the 100% mark over this same time period -- including JPMorgan Chase, Goldman Sachs, Wells Fargo, and PNC Financial -- and roughly half of the 100-plus banks I examined actually declined in value over the same time period.

Top 10 Consumer Service Stocks For 2016: Allegiant Travel Co (ALGT)

Allegiant Travel Company, incorporated on April 4, 2006, is a leisure travel company focused on providing travel services and products to residents of small, underserved cities in the United States. The Company operates a passenger airline marketed primarily to leisure travelers in small cities, allowing it to sell air transportation both on a stand-alone basis and bundled with the sale of air-related and third party services and products. In addition, it provides air transportation under fixed fee flying arrangements. The Company provides scheduled air transportation on limited frequency nonstop flights between small city markets and leisure destinations. As of February 1, 2013, its operating fleet consisted of 58 MD-80 aircraft and six Boeing 757-200 aircraft providing service on 191 routes to 85 cities including 13 leisure destinations and 72 small cities and including cities served seasonally. In January 2012, the Company took ownership of two MD-80 aircraft. In October 2012, the Company announced the formation of Allegiant Systems, a joint venture with AvIntel and Lixar IT.

The Company provides unbundled air-related services and products in conjunction with air transportation for an additional cost to customers. These optional air-related services and products include use of its Website for purchases, use of its call center for purchases, advance seat assignment, baggage fees, priority boarding, its own travel protection product, change fees, food and beverage purchases on board and other air-related services. The Company offers third party travel products, such as hotel rooms, ground transportation (rental cars and hotel shuttle products) and attractions (show tickets) bundled with the purchase of its air transportation.

The Company provides air transportation through fixed fee agreements and charter service on a seasonal and ad-hoc basis for other customers. As of February 1, 2013, its operating aircraft consisted of 58 MD-80 aircraft and six Boeing 757-200 aircraft. D! uring the year ended December 31, 2012, the Company has entered into purchase agreements to acquire seven Airbus A320 aircraft and operating lease agreements for an additional nine Airbus A319 aircraft.

The Company competes with AirTran, Frontier, Spirit, Southwest, US Airways, Alaska Airlines, Horizon Air, Delta, Xtra, United and American.

Advisors' Opinion:
  • [By Ben Levisohn]

    DeNardi also rates Alaska Air (ALK), Spirit Airlines (SAVE) and Allegiant Travel (ALGT) as Buys and Southwest, JetBlue Airways (JBLU) and Hawaiian Holdings (HA) as holds.

Hot Life Sciences Companies To Invest In Right Now: Stewart Enterprises Inc.(STEI)

Stewart Enterprises, Inc., through its subsidiaries, provides funeral and cemetery products and services in the death care industry in the United States and Puerto Rico. The company also offers a range of funeral merchandise and services, as well as cemetery property, cremation, merchandise, and services. Its funeral homes provide various services and products, including the family consultation, removal and preparation of remains, usage of funeral home facilities for visitation, worship and funeral services, transportation services, flowers, and caskets. The company also sells cemetery property and related merchandise, which includes lots, lawn crypts, family and community mausoleums, monuments, markers, and burial vaults; and provides burial site openings and closings and inscriptions. In addition, it maintains cemetery grounds under cemetery perpetual care contracts and local laws. As of January 31, 2011, the company owned and operated 218 funeral homes and 141 cemeterie s. Stewart Enterprises, Inc. was founded in 1910 and is based in Jefferson, Louisiana.

Advisors' Opinion:
  • [By Chris Katje]

    Service Corporation (SCI), the largest funeral home operator in the United States, made news last week with its large acquisition of Stewart Enterprises (STEI). The acquisition was well received by investors, as shares rose 8% on the day of the announcement. Together, the two companies will see huge cost savings advantages and a backlog that is currently undervalued.

  • [By Brian Pacampara]

    What: Shares of funeral-home operator Stewart Enterprises (NASDAQ: STEI  ) soared 34% today, after larger rival Service Corp. International (NYSE: SCI  ) agreed to acquire it in a deal worth about $1.4 billion.

Hot Life Sciences Companies To Invest In Right Now: Repligen Corporation(RGEN)

Repligen Corporation engages in the manufacture and supply of biologic products used to manufacture biologic drugs. The company offers commercial bioprocessing products based on protein A and IFG-1 growth factors; and pre-packed chromatography columns under the Opus brand, which are used in the production of monoclonal antibodies and other biopharmaceutical products. It also develops SecreFlo, a synthetic human hormone that has completed a Phase III clinical trial and is to be used in combination with magnetic resonance imaging to improve the detection of pancreatic abnormalities in patients with pancreatitis; RG3039, which is in Phase I study for the treatment of patients with spinal muscular atrophy; and RG2833, a class I histone deacetylase inhibitor that is in Phase I study for the treatment of patients with Friedreich?s ataxia. In addition, the company licenses its biologics intellectual property to Bristol-Myers Squibb Company. Repligen Corporation sells its bioproc essing products to life science companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers through its direct sales force, partners, and distributors in certain foreign markets. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Advisors' Opinion:
  • [By Brian Pacampara]

    Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, small-cap biotech Repligen (NASDAQ: RGEN  ) has earned a coveted five-star ranking.

Hot Life Sciences Companies To Invest In Right Now: NewLink Genetics Corp (NLNK)

NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.

The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.

HyperAcute Cancer Immunotherapy Product Candidates

In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.

HyperAcute Cancer Immunotherapy Technology

The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.

IDO Pathway Inhibitor Product Candidate

The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    In trading on Thursday, healthcare shares were relative laggards, down on the day by about 0.64 percent. Top decliners in the sector included Sunesis Pharmaceuticals (NASDAQ: SNSS), off 5.6 percent, and NewLink Genetics (NASDAQ: NLNK), down 6.3 percent.

Hot Life Sciences Companies To Invest In Right Now: dELIA*s Inc.(DLIA)

dELiA*s, Inc. operates as a direct marketing and retail company in the United States. It offers a collection of apparel, dresses, swimwear, roomwear, footwear, outerwear, and key accessories primarily for teenage girls. The company sells its products through direct mail catalogs, Websites, and mall-based specialty retail stores under the dELiA*s brand name. As of January 29, 2011, it operated 114 dELiA*s retail stores. The company also markets and sells branded junior apparel, dresses, accessories, swimwear, footwear and outerwear primarily to young women through catalogs and Internet under the Alloy brand name. dELiA*s, Inc. was founded in 1997 and based in New York, New York.

Advisors' Opinion:
  • [By Sean Williams]

    Don't fight history
    Sometimes we just have to remember as investors that there isn't room enough for every company to succeed. Thus enters dELiA*s (NASDAQ: DLIA  ) , an online and mail catalog retailer that markets apparel to teenage girls and young women.

  • [By Eric Volkman]

    dELIA*s (NASDAQ: DLIA  ) is now a lighter company following the divestment of one of its brand lines. The company announced that it has sold its Alloy subsidiary to HRSH Acquisitions, which is conducting business under the name Alloy Apparel and Accessories. dELIA*s was paid $3.7 million in cash for the unit, and the buyer will assume roughly $3.1 million in liabilities.

Hot Life Sciences Companies To Invest In Right Now: Central European Media Enterprises Ltd.(CETV)

Central European Media Enterprises Ltd., a media and entertainment company, operates broadcast, content, and new media businesses in central and eastern Europe. The company operates in three segments: Broadcast, Media Pro Entertainment, and New Media. The Broadcast segment operates 30 television channels reaching an aggregate of approximately 49 million people primarily in 6 countries. It operates television channels, including BTV, BTV CINEMA, BTV COMEDY, RING.BG, BTV ACTION, and BTV LADY, a female-oriented cable channel in Bulgaria; NOVA TV, DOMA, and NOVA WORLD in Croatia; TV NOVA, NOVA CINEMA, NOVA SPORT, and MTV CZECH in the Czech Republic; PRO TV, PRO TV INTERNATIONAL, ACASA, PRO CINEMA, MTV ROMANIA, PRO TV CHISINAU, and SPORT.RO in Romania; TV MARK�A and DOMA in the Slovak Republic; POP TV, KANAL A, and POP BRIO in Slovenia, as well as various radio channels in Bulgaria. The Media Pro Entertainment segment develops, produces, and distributes content for its own te levision channels, as well as to third parties through the theatrical and home video operations; sells DVD and Blu Ray discs to wholesale and retail clients; and distributes theatrical, home entertainment, digital, and television film rights. It also owns and operates 16 cinema screens in Romania. The New Media segment offers television content; and operates various news portals, niche Websites, and television-related Websites. Central European Media Enterprises Ltd. was founded in 1994 and is based in Hamilton, Bermuda.

Advisors' Opinion:
  • [By Roberto Pedone]

    Central European Media Enterprises (CETV) is a media and entertainment company that operates broadcast, content and new media businesses in central and Eastern Europe. This stock closed up 5.1% to $3.68 in Thursday's trading session.

    Thursday's Range: $3.50-$3.80

    52-Week Range: $2.60-$7.92

    Thursday's Volume: 365,000

    Three-Month Average Volume: 741,458

    From a technical perspective, CETV bounced sharply higher here right off its 50-day moving average of $3.42 with lighter-than-average volume. This move is quickly pushing shares of CETV within range of triggering a major breakout trade. That trade will hit if CETV manages to take out some near-term overhead resistance levels at $3.79 to $3.89 with high volume.

    Traders should now look for long-biased trades in CETV as long as it's trending above its 50-day at $3.42 or above more near-term support at $3.25 and then once it sustains a move or close above those breakout levels with volume that hits near or above 741,458 shares. If that breakout hits soon, then CETV will set up to re-test or possibly take out its next major overhead resistance levels at $4.45 to $4.68. Any high-volume move above those levels will then put its next major overhead resistance levels at $5 to $5.25 into range for shares of CETV.

  • [By Monica Gerson]

    Central European Media Enterprises (NASDAQ: CETV) dipped 5.84% to $3.55 in the pre-market session. Central European Media's trailing-twelve-month ROE is -70.51%.

No comments:

Post a Comment